Key results at 80 weeks: Participants on the 4 mg dose lost an average of 47.2 lbs (19.0%) Participants on the 12 mg dose lost an average of 70.3 lbs (28.3%) 45.3% of participants on the 12 mg dose achieved at least 30% weight loss a level historically associated with bariatric surgery outcomes The 4 mg dose showed a lower rate of discontinuation due to adverse events than even placebo In a study extension to 104 weeks, participants with a starting BMI of 35 or higher who received 12 mg lost up to an average of 85.0 lbs (30.3%)
Planning ahead matters significantly
Switching protocols are currently being established in clinical trials
Inoue M, Hara M, Nagashima F, Matsui S, Mitsuyasu N, Morino Y: Affinity chromatography of hepatic glutathione S-transferases on omega-aminoalkyl sepharose derivatives of glutathione
1C, D), supporting prior data showing that activation of this pathway results in resistance to CDK4/6 inhibitors 18,19,22,23,24
The practical implication is that AOD-9604 works best as a component of a comprehensive approach rather than as a standalone dramatic weight loss intervention